Clinical trials: Ovary Disease
Polycystic Ovary Syndrome
Simvastatin and Metformin Therapy in PCOS Women. Prospective Randomised Trial.
The purpose of this study is to compare effects of statins (simvastatin) and metformin on clinical (menstrual cycle, excessive hair, skin problems), endocrine (androgens), metabolic (lipids, markers of systemic inflammation), and…
- Trial name
- NCT00396513
- Testing
- Simvastatin, Simvastatin and Metformin, Metformin
- Where
- Poland
- Sponsor
- Poznan University of Medical Sciences
Ovarian Cancer
Combination Chemotherapy Plus Peripheral Stem Cell Transplantation in Treating Patients With Stage III or Stage IV Ovarian Cancer
RATIONALE: Drugs used in chemotherapy use different ways to stop tumor cells from dividing so they stop growing or die. Combining chemotherapy with peripheral stem cell transplantation may allow the doctor to give higher doses of…
- Trial name
- NCT00003297
- Testing
- mitoxantrone hydrochloride, thiotepa, topotecan hydrochloride
- Where
- United States
- Volunteers
- 50 people
- Sponsor
- Georgetown University
Solid Tumors
Cardiac Safety Assessment Study of Picoplatin in Solid Tumors
The purpose of this study is to investigate what effects, if any, picoplatin has on the heart rhythm.
- Trial name
- NCT00710697
- Testing
- Picoplatin
- Where
- 7 sites in United States
- Volunteers
- 40 people
- Sponsor
- Poniard Pharmaceuticals
Ovarian Cancer
Niraparib Maintenance Treatment in Patients With Newly Diagnosed Advanced Platinum- Sensitive, OC. The First Poland RWE Study.
The study is observational, not interventional. The study will include patients with advanced ovarian cancer who have been treated in Poland based on a previous early access program, and who are currently being treated under the…
- Trial name
- NIRAPARIB (NCT06614790)
- Testing
- Niraparib 200/300 MG
- Where
- 12 sites in Poland
- Volunteers
- 300 people
- Sponsor
- Pomeranian Medical University Szczecin
Polycystic Ovary Syndrome
Effect of Magnesium Supplementation on Polycystic Ovary Syndrome
This is a double-blind randomized clinical trial which will start at June 2014 and end on June 2015 in Isfahan city. Serum insulin level is considered as a key variable and the sample size calculated 70 persons (35 persons for…
- Trial name
- NCT02178150
- Testing
- Magnesium Oxide
- Where
- Iran
- Volunteers
- 70 people
- Sponsor
- Isfahan University of Medical Sciences
Cancer Harboring BRAF Alterations, HGG
A Study to Assess the Efficacy and Safety of FORE8394 in Participants With Cancer Harboring BRAF Alterations
The objective of this Master Protocol is to evaluate the efficacy and safety of plixorafenib in participants with BRAF altered (BRAF V600E or BRAF fusions) locally advanced or metastatic solid tumors, or recurrent or progressive…
- Conditions
- Cancer Harboring BRAF Alterations, HGG, LGG, Solid Tumors
- Trial name
- NCT05503797
- Testing
- Plixorafenib
- Where
- 70 sites in United States, Australia and 10 more
- Volunteers
- 254 people
- Sponsor
- Fore Biotherapeutics
Ovarian Cysts
Laparoscopy-assisted Ovarian Cystectomy: NEW APPROCH
Under general anaesthesia, the patient is placed in the modified dorsal lithotomy position a 10-mm umbilical trocar is inserted. A panoramic view of the pelvis was obtained together with full assessment of the ovarian mass(es).
- Trial name
- NCT03370952
- Testing
- laproscopy, combined laproscopic and minilaparotomy ovarian cystectomy
- Where
- Egypt
- Volunteers
- 112 people
- Sponsor
- Cairo University
Ovulation Induction
Recombinant Follicle Stimulating Hormone (FSH) (Gonal-f®): Use in Ovulation Induction
This is an open-label, prospective, randomized, controlled, multicentric, multinational, phase IV study to evaluate the use of Gonal-f in inducing ovulation in female subjects with chronic anovulation.
- Trial name
- NCT01081626
- Testing
- Recombinant FSH (follitropin alpha)
- Where
- 3 sites in Kuwait, Lebanon and 1 more
- Volunteers
- 310 people
- Sponsor
- Merck KGaA, Darmstadt, Germany
Pancreatic Ductal Adenocarcinoma, Non-small Cell Lung Cancer
A Study of the Pan-KRAS Inhibitor LY4066434 in Participants With KRAS Mutant Solid Tumors
The main purpose of the study is to assess whether the study drug, LY4066434, is safe and tolerable when administered to participants with locally advanced or metastatic solid tumors with certain KRAS mutations.
- Conditions
- Pancreatic Ductal Adenocarcinoma, Non-small Cell Lung Cancer, Colorectal Cancer, Advanced Solid Tumor
- Trial name
- NCT06607185
- Testing
- LY4066434., Cetuximab, Nab paclitaxel
- Where
- 45 sites in United States, Belgium and 6 more
- Volunteers
- 750 people
- Sponsor
- Eli Lilly and Company
Polycystic Ovary Syndrome, Metabolic Syndrome
Study of the Effect of a Nutritional Supplement on Microbiota, Metabolic Control, Inflammatory Profile, and Quality of Life in Patients With Polycystic Ovary Syndrome.
Polycystic Ovary Syndrome (PCOS) is a complex endocrine-metabolic disorder characterized by elevated androgen levels due to ovarian overproduction.
- Trial name
- NCT06551285
- Testing
- Ovapro (Lifepro)
- Where
- Spain
- Volunteers
- 120 people, healthy volunteers welcome
- Sponsor
- Celia Bañuls
Ovarian Cancer
Bryostatin 1 in Treating Patients With Ovarian Epithelial Cancer
RATIONALE: Drugs used in chemotherapy use different ways to stop cancer cells from dividing so they stop growing or die. PURPOSE: Phase II trial to study the effectiveness of bryostatin 1 in treating patients who have ovarian…
- Trial name
- NCT00004008
- Testing
- bryostatin 1
- Where
- 4 sites in United Kingdom
- Sponsor
- University of Glasgow
Polycystic Ovary Syndrome
A Reduced Carbohydrate Diet Intervention for Polycystic Ovary Syndrome (PCOS)
Polycystic ovary syndrome (PCOS) affects 5-10% of women of reproductive age, and is associated with infertility, risk for obesity and type 2 diabetes, and impaired quality of life.
- Trial name
- NCT01028989
- Testing
- Reduced Glycemic Load Diet, Standard Diet
- Where
- United States
- Volunteers
- 23 people, healthy volunteers welcome
- Sponsor
- University of Alabama at Birmingham
Endometrial Cancer, Ovarian Cancer
Temozolomide in Treating Patients With Advanced Soft Tissue Sarcoma
RATIONALE: Drugs used in chemotherapy use different ways to stop cancer cells from dividing so they stop growing or die. PURPOSE: Phase II trial to study the effectiveness of temozolomide in treating patients who have advanced…
- Conditions
- Endometrial Cancer, Ovarian Cancer, Sarcoma
- Trial name
- NCT00003718
- Testing
- temozolomide
- Where
- United States
- Volunteers
- 25 people
- Sponsor
- Herbert Irving Comprehensive Cancer Center
Polycystic Ovary Syndrome
A Study to Evaluate the Effect of Elix Cycle Balance and Daily Harmony on Polycystic Ovary Syndrome
This is a virtual, open-label, 2-armed study that will last 6 months. All participants will take the supplements daily and complete questionnaires at baseline and at the end of weeks 4, 8, 12, 16, 20, and 24 (study may be…
- Trial name
- NCT05875233
- Testing
- Elix Daily Harmony, Elix Cycle Balance
- Where
- United States
- Volunteers
- 70 people, healthy volunteers welcome
- Sponsor
- Zenchi, Inc.
Ovarian Cancer, Fallopian Tube Cancer
Pembrolizumab Combined With PLD For Recurrent Platinum Resistant Ovarian, Fallopian Tube Or Peritoneal Cancer
This research study is studying the combination of Pegylated Liposomal Doxorubicin (PLD) and Pembrolizumab as a possible treatment for Recurrent Ovarian, Fallopian Tube or Peritoneal Cancer that is resistant to platinum therapy.
- Conditions
- Ovarian Cancer, Fallopian Tube Cancer, Peritoneal Cancer
- Trial name
- NCT02865811
- Testing
- Pembrolizumab, Pegylated Liposomal Doxorubicin (PLD)
- Where
- 3 sites in United States
- Volunteers
- 26 people
- Sponsor
- Dana-Farber Cancer Institute
Solid Tumors
DB-1311 in Combination With BNT327 or DB-1305 in Advanced/Metastatic Solid Tumors
A Phase II, Multicenter, Open-Label Trial of DB-1311 in combination with BNT327 or DB-1305 in Participants with Advanced/Metastatic Solid Tumors
- Trial name
- NCT06953089
- Testing
- DB-1311/BNT324, BNT327, DB-1305/BNT325
- Where
- 37 sites in United States, Australia and 2 more
- Volunteers
- 750 people
- Sponsor
- DualityBio Inc.
Epithelial Ovarian Cancer, Gastric Adenocarcinoma
Phase I-II, FIH, TROP2 ADC, Advanced Unresectable/Metastatic Solid Tumors, Refractory to Standard Therapies (KL264-01)
A Phase I-II, First-in-Human Study of SKB264 (Sac-TMT; MK-2870) in Patients with Locally Advanced Unresectable/Metastatic Solid Tumors who are refractory to Available Standard Therapies.
- Conditions
- Epithelial Ovarian Cancer, Gastric Adenocarcinoma, Gastroesophageal Junction Adenocarcinoma, Urothelial Carcinoma
- Trial name
- MK-2870-001 (NCT04152499)
- Testing
- SKB264
- Where
- 109 sites in United States, Canada and 4 more
- Volunteers
- 1,410 people
- Sponsor
- Klus Pharma Inc.
Cervical Cancer, Gastric/Gastroesophageal Junction Adenocarcinoma
A Study of BMS-986340 as Monotherapy and as Combination Therapy in Participants With Advanced Solid Tumors
The purpose of this study is to assess the safety, tolerability, and recommended dose(s) of BMS-986340 as monotherapy and in combination with nivolumab, docetaxel, or Pumitamig in participants with advanced solid tumors.
- Conditions
- Cervical Cancer, Gastric/Gastroesophageal Junction Adenocarcinoma, Microsatellite Stable Colorectal Cancer, Non-Small-Cell Lung Cancer
- Trial name
- NCT04895709
- Testing
- BMS-986340, BMS-936558-01, Docetaxel
- Where
- 47 sites in United States, Australia and 6 more
- Volunteers
- 1,109 people
- Sponsor
- Bristol-Myers Squibb
Familial Breast Cancer, Familial Colorectal Cancer
Direct Information to At-risk Relatives
This study evaluates if uptake of genetic counselling in high-risk families is increased when patients at cancer genetics clinics are being offered healthcare-assisted disclosure to at-risk relatives compared to current standard…
- Conditions
- Familial Breast Cancer, Familial Colorectal Cancer, Hereditary Breast and Ovarian Cancer Syndrome, Hereditary Breast Cancer
- Trial name
- DIRECT (NCT04197856)
- Testing
- Standard care encouraging family-mediated disclosure of hereditary cancer risk, Offer of health-care assisted disclosure by sending direct letters to at-risk relatives
- Where
- Sweden
- Volunteers
- 490 people
- Sponsor
- Umeå University
Endometriosis, Adhesion
Ovariopexy for Adhesion Prevention After Laparoscopic Removal of Endometriosis of the Pelvic Side Wall or the Ovary
prospective randomized Trial comparing ovariopexy over 2, 4 or 6 days vs Placebo after surgery because of endometriosis of the pelvic side wall or the ovary or both
- Conditions
- Endometriosis, Adhesion, Surgery
- Trial name
- NCT04669756
- Testing
- ovariopexy
- Where
- Germany
- Volunteers
- 409 people
- Sponsor
- University Hospital Muenster
The first 1,020 results can be paged through. Add a filter or change the sort order to reach the rest.